These results in patients with high PD-L1-expressing advanced NSCLC emulate immune checkpoint inhibitor (ICI) monotherapy, which provides significant clinical benefit, and it will require a randomized trial to discern the value, if any, of adding adagrasib to an effective ICI monotherapy regimen. The gene discussed is CD274; the disease is non-small cell lung carcinoma.